-- Tecentriq significantly improved overall survival in people with high
PD-L1 expression, compared with chemotherapy in a Phase III study
-- Tecentriq approval offers an alternative to chemotherapy for all eligible
patients
-- This approval marks Tecentriq's fourth indication in metastatic non-small
cell lung cancer and fifth indication in lung cancer overall in the EU
https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Press-Release-nbsp-Roche-s-Tecentriq-approved-by-European-Commission-as-a-first-line-monotherapy-t-33159989/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.